Clinical response evaluation after neoadjuvant chemoradiotherapy in esophageal cancer
Recruiting
- Conditions
- English: Squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction.Dutch: Plaveiselcel- of adenocarcinoom van de slokdarm of gastro-oesophageale overgang.
- Registration Number
- NL-OMON21053
- Lead Sponsor
- Erasmus MC – University Medical Center RotterdamAcademic Medical Center AmsterdamUniversity Medical Center UtrechtCatharina Cancer Center EindhovenAtrium Medical Center Heerlen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
Patients who are planned to undergo neoadjuvant chemoradiotherapy according to CROSS, followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma are eligible for this study.
Exclusion Criteria
Dementia or altered mental status prohibiting the understanding and giving of informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study parameter is the correlation between the clinical response during CRE-I and CRE-II (CRE= clinical response evaluation) and the final pathological response in the resection specimen (as measured by the modified tumour regression grading system of Chirieac).
- Secondary Outcome Measures
Name Time Method R0-resection rates for all included patients that undergo resection.